Clinical and Morphological Characteristics of the Prostate Gland During Treatment with 5-Alpha Reductase Inhibitors for BPH

    January 2012 in “ Земский врач ”
    N. G. Kulchenkо, К. И. Бичерова, Alexandr Strachuk, И. Е. Гудкова
    TLDR Finasteride helps improve treatment for benign prostatic hyperplasia.
    The study analyzed the effects of finasteride, a 5-alpha-reductase inhibitor, on 65 men with benign prostatic hyperplasia (BPH), with an average age of 64. Over 6 months, 35 men received finasteride, while 30 were under observation without medication. Results showed significant improvements in urinary symptoms and quality of life in the finasteride group, with a 22.2% reduction in IPSS scores and a 30.2% improvement in QoL scores. Prostate volume decreased by 18.7%, and PSA levels dropped by 25.6% after 6 months. Morphological changes included increased fibrosis and reduced glandular tissue volume, suggesting finasteride's potential in reducing prostate cancer risk. However, 34.2% of the treatment group and 53.3% of the control group withdrew due to worsening symptoms, highlighting the need for careful patient selection.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 2 years ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Wtf have we been doing for the last 30 years

      in Treatment  548 upvotes 11 months ago
      Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

    Similar Research

    5 / 1000+ results